CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

CytoDyn, Inc. announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.